Actinium Pharmaceuticals, Inc.(ATNM)

Description: Actinium Pharmaceuticals, Inc., formerly Cactus Ventures, Inc. is a biopharmaceutical company developing cancer drugs. The Company's advanced products are Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), in human clinical trials for acute myeloid leukemia (AML) and Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications. In addition, the Ac-225 based drugs development relies on the patented Alpha Particle Immunotherapy Technology (APIT) platform technology co-developed with Memorial Sloan- Kettering Cancer Center (MSKCC), a related institution. The APIT technology couples monoclonal antibodies (mAb) with extremely potent but comparatively safe alpha particle emitting radioactive isotopes, in particular actinium 225 and bismuth 213.

---

Keywords: Natural Sciences Chemical Elements Cancer Biopharmaceutical Immunology Antibodies Immunotherapy Monoclonal Antibodies Stem Cell Monoclonal Antibody Acute Myeloid Leukemia Transplantation Platform Technology Actinides Bismuth Hematopoietic Stem Cell Cancer Center Iodine Astatine Cactus Immunotherapy Technology Kettering Cancer Center Memorial Sloan

---

Home Page: www.actiniumpharma.com

ATNM Technical Analysis

275 Madison Avenue
New York, NY 10016
United States
Phone: 646 677 3870

---

Officers

Exchange: NYSE MKT

Country: US

Currency: US Dollar ($)